The results underline the importance of expanding the NGS approach in gallbladder cancer in order to propose new molecular markers of predisposition and prognosis exploitable by novel targeted therapies that may improve the response of patients with <i>ATM</i>-deficient cancers. This evidence concerns the gene ATM and cancer.